ArticleJournal of experimental & clinical cancer research : CR2022

FAM167A is a key molecule to induce BCR-ABL-independent TKI resistance in CML via noncanonical NF-κB signaling activation.

Taewoo Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.